[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.158.163. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
August 2005

Reexamination of the TEMPO Study

Arch Neurol. 2005;62(8):1320. doi:10.1001/archneur.62.8.1320

Recent claims in the lay press that rasagiline (N-propargyl-1[R]-aminoindan) mesylate (TVP-1012) can reduce the progressive functional decline in patients with Parkinson disease prompted a colleague to ask me to look again at the article reporting the results of the TEMPO study.1 Examination of the article raised a concern regarding the inclusion of certain subjects in the primary analysis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×